What are the indications and side effects of macrolide antibiotics?

Macrolides: Indications and Side Effects

Macrolide antibiotics are primarily indicated for respiratory tract infections (including community-acquired pneumonia, bronchiectasis, and COPD exacerbations), with long-term low-dose therapy showing benefit in reducing exacerbations in chronic respiratory diseases, but their use is limited by significant gastrointestinal side effects (occurring in up to 70% of patients) and potentially life-threatening cardiac arrhythmias from QT prolongation. 1

Primary Indications

Acute Infections

• Community-acquired pneumonia (CAP): Macrolides target atypical pathogens (Mycoplasma, Chlamydia, Legionella) and provide immunomodulatory benefits in severe CAP 2
• Respiratory tract infections: Broad coverage including Gram-positive organisms and atypical bacteria
• Skin and soft tissue infections: Alternative for β-lactam allergic patients

Long-Term Prophylactic Use (Low-Dose Therapy)

COPD: Consider azithromycin for patients with ≥3 exacerbations requiring steroids annually AND ≥1 hospitalization per year. Use 250-500 mg three times weekly for 6-12 months to assess benefit 1

Bronchiectasis: Offer long-term therapy for patients with ≥3 exacerbations per year. Evidence-based regimens include:

• Azithromycin 500 mg three times weekly
• Azithromycin 250 mg daily
• Erythromycin 400 mg twice daily 1

Bronchiolitis obliterans syndrome (BOS): Azithromycin 250 mg three times weekly for prevention post-lung transplant, or 250 mg alternate days for 3 months to treat established BOS 1

Severe asthma: Azithromycin can be added for uncontrolled non-T2 severe asthma despite maximal inhaled therapy, or in T2 asthma uncontrolled on biologics 3

Major Side Effects

Gastrointestinal Effects (Most Common)

Mechanism: Macrolides interact with motilin receptors causing prokinetic effects, NOT alterations in gut flora 1

Incidence and specific effects:

• Occurs in up to 70% with erythromycin, less with clarithromycin and azithromycin 1
• Gastrointestinal disorders NOS: 85 additional cases per 1000 patients (NNTH = 12)
• Diarrhea: 72 additional cases per 1000 (NNTH = 19)
• Abdominal pain: 62 additional cases per 1000 (NNTH = 17)
• Nausea: 47 additional cases per 1000 (NNTH = 19)
• Vomiting: 23 additional cases per 1000 (NNTH = 45) 4

Clinical significance: Despite high frequency, GI symptoms rarely necessitate discontinuation. Dose reduction may improve tolerability but may reduce efficacy 1

Cardiac Effects (Most Serious)

Mechanism: Direct QT interval prolongation AND inhibition of cytochrome P450, potentiating other proarrhythmic drugs 1

High-risk factors for malignant arrhythmias:

• Age >80 years
• Female gender
• Pre-existing heart disease
• Concurrent QT-prolonging medications
• Reduced drug elimination (renal/hepatic impairment)
• Bradycardia
• Baseline prolonged QT interval
• Genetic predisposition
• Hypokalemia 1

Absolute risk: 85 deaths per 1 million courses in high-risk populations 1

Mandatory screening protocol 1:

1. Before initiation:

   • ECG to measure QTc (contraindicated if >450 ms men, >470 ms women)
   • Screen for cardiac history, family history of sudden death, slow pulse, previous hypokalemia
   • Review all medications for QT-prolonging agents
   • Baseline liver function tests

2. One month after starting: Repeat ECG to detect new QTc prolongation (stop if develops)

3. Ongoing: Repeat ECG if any new QT-prolonging drug added or dose increased

Other Significant Side Effects

Hearing and balance disturbances: Ototoxicity can occur, almost always reversible. Screen for pre-existing hearing/balance problems before initiation 1

Taste disturbances: Increased risk (OR 4.95% CI 1.64-14.93), though with wide confidence intervals 4

Hepatobiliary effects: No clear increased risk of hepatobiliary disorders (OR 1.04) or liver enzyme changes (OR 1.56) compared to placebo 4

Antimicrobial resistance: Macrolide-resistant bacteria more common immediately after exposure. Screen sputum for nontuberculous mycobacteria (NTM) before starting—avoid macrolide monotherapy if NTM present 1

Critical Safety Monitoring

Baseline requirements:

• ECG (QTc measurement)
• Liver function tests
• Sputum culture (if productive) including NTM screening
• Medication review for drug interactions
• Cardiac and hearing history 1

Follow-up schedule:

• 1 month: ECG, liver function tests
• 6 months: Liver function tests, assess clinical benefit
• 12 months: Assess benefit using objective measures (exacerbation rate, validated quality of life scores like CAT or SGRQ)
• Stop if no benefit demonstrated 1

Important Clinical Caveats

Contraindications to long-term therapy:

• Baseline QTc >450 ms (men) or >470 ms (women)
• Concurrent use of other QT-prolonging medications
• Severe cardiac disease without specialist consultation
• Identified NTM without appropriate multi-drug regimen 1

Optimize before starting: Ensure maximal disease-specific therapy first (inhaler technique, airway clearance, pulmonary rehabilitation, smoking cessation) 1

Drug holidays: Consider stopping treatment periodically (e.g., summer months) to reduce resistance development while maintaining efficacy by breaking the inflammatory cycle 1

No mortality benefit: Long-term macrolide use shows no increase in mortality (OR 0.96,95% CI 0.87-1.06) but also no mortality reduction 4